Newly Granted Patent Application improves Patient Compliance
- May 27, 2025
- 2 min read
San Francisco, May 27, 2025 - Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and other diseases, announced that the European Patent Office has granted the new patent with the potential of significantly improving administration of the company’s lead drug candidate Dutogliptin.
The European Patent Office (EPO) has granted to Recardio in May a new patent, published as EP 4 514 359 B1. The patent relates to a novel formulation process of the company’s lead drug candidate Dutogliptin and was developed by the company in the past years.
Compared to the current daily application mode, this new formulation will enable a once per week administration in the targeted therapeutic setting and beyond resulting in potential significant easy use and compliance benefits for the patients.
This newly granted patent is extending Recardio’s patent protection for Dutogliptin into 2045 and the company is already in the process of converting this patent globally into national patents applications in key markets.
About Recardio
Recardio Inc. is a late-stage clinical biotechnology company focused on developing therapies for cardiometabolic and other diseases through a therapeutic platform, designed for disease modification and regeneration.
The company is located in San Francisco, California, with operations in the USA and Europe.
Recardio’s lead drug candidate, dutogliptin, a DPP-IV inhibitor, has demonstrated efficacy in promoting endogenous disease-modifying cardiac regeneration and supporting tissue repair following cardiac injury. The FDA and EMA have approved the global pivotal Phase 3 HEAL-AMI clinical program in acute myocardial infarction for regulatory authorization in major markets.
In addition, the company is advancing multiple cardiometabolic programs in clinical and preclinical development.
For more information, visit: http://www.recardio.eu/ or contact pr@recardio.eu
